Clinical trial · Observational
Tumor and Development (TED)
Identification of Patients/Families With a Paediatric Tumor and One or More Developmental Abnormalities - Characterization of New Tumor Predisposition Syndromes and Study Their Molecular Basis
NCT01915797CI-TRIAL-00103306TEDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall project goal is to build a database of childhood cancers associated with developmental anomalies; it aims at identifying new syndromes of genetic predisposition and at enabling the further study of their molecular basis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor and Abnormalities of the Development | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood and tumor samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient having a cancer and abnormal development
- description
- Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
- interventionNames
- Other: blood and tumor samples
Primary outcomes (1)
- measure
- Registration of developmental abnormalities in pediatric patients with cancer retrospectively and prospectively for a period of three years on a nationwide scale
- timeFrame
- Day 0
Secondary outcomes (2)
- measure
- to record tumoral pathologies in known contexts of cancer predisposition
- timeFrame
- Day 0
- measure
- to record tumoral pathologies occurring in association with one or more developmental anomaly, these associations might have been already described or not
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Days
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria : \- Patient who developed before the age of 18 years a solid tumour or a malignant or borderline hemopathy. AND * Presenting one or several abnormality (ies) of the development provided it is not related to the treatment and\\or to the disease among: * organ malformation, familial or not * neuro-sensory deficit, familial or not * delay of psychomotor acquisitions * epilepsy (not as a sequelae of the tumour) * disorder of growth and\\or weight and\\or of the cranial perimeter * congenital, sporadic and\\or familial endocrine or metabolic disease * dysmorphy * Informed consent of patient and parents to this study OR * tumour predisposition syndrome or developmental abnormality in a familial context, the molecular basis might have been already identified or not Exclusion Criteria: * absence of malignancy in the index case * lack of developmental anomalies in the index case or in a related first degree * abnormal development recognized as acquired (traumatic, toxic, infectious, perinatal…) * age \> 18 years at diagnosis of the tumor * Lack of informed consent of the legal representatives The familial aggregations of cancer without developmental disease are not included in this study.
References
Publications (1)
- RESULTSemeraro M, Fouquet C, Vial Y, Amiel J, Galmiche L, Cretolle C, Blanc T, Jolaine V, Garcelon N, Entz-Werle N, Pellier I, Verite C, Sophie Taque, Coulomb A, Petit A, Corradini N, Bouazza N, Lacour B, Clavel J, Brugieres L, Bourdeaut F, Sarnacki S; members of the TED Consortium. Pediatric Tumors and Developmental Anomalies: A French Nationwide Cohort Study. J Pediatr. 2023 Aug;259:113451. doi: 10.1016/j.jpeds.2023.113451. Epub 2023 May 9. PMID 37169337